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Cancer stem cells drive tumor formation and metas-
tasis, but how they acquire metastatic traits is not
well understood. Here, we show that all colorectal
cancer stem cells (CR-CSCs) express CD44v6, which
is required for their migration and generation of met-
astatic tumors. CD44v6 expression is low in primary
tumors but demarcated clonogenic CR-CSC popu-
lations. Cytokines hepatocyte growth factor (HGF),
osteopontin (OPN), and stromal-derived factor 1a
(SDF-1), secreted from tumor associated cells, in-
crease CD44v6 expression in CR-CSCs by activating
the Wnt/b-catenin pathway, which promotes migra-
tion and metastasis. CD44v6 progenitor cells do
not give rise to metastatic lesions but, when treated
with cytokines, acquire CD44v6 expression and met-
astatic capacity. Importantly, phosphatidylinositol
3-kinase (PI3K) inhibition selectively killed CD44v6
CR-CSCs and reduced metastatic growth. In patient
cohorts, low levels of CD44v6 predict increased
probability of survival. Thus, the metastatic process
in colorectal cancer is initiated by CSCs through
the expression of CD44v6, which is both a functional
biomarker and therapeutic target.
INTRODUCTION
Due to the extreme difficulties to cure distant metastasis, colo-
rectal cancer (CRC) is the second leading cause of cancer
death in Western countries (Jemal et al., 2011). The complex
mechanisms leading to cancer metastasis are far from being
completely understood, and it is still unclear which cell subset
is able to migrate, survive, and grow at the metastatic site
(Chaffer and Weinberg, 2011).
In recent years, a growing body of evidence has provided sup-
port for the existence of cellular hierarchies within many tumor
types where cancer stem cells (CSCs), commonly identified by342 Cell Stem Cell 14, 342–356, March 6, 2014 ª2014 Elsevier Inc.their cell-surface-marker expression, are the unique source
of all tumor cells and responsible for tumor propagation and
relapse (Valent et al., 2012). CSCs, defined by their capacity
for self-renewal and resistance to conventional chemotherapies,
are believed to remain after cancer therapy to initiate the meta-
static process (Brabletz et al., 2005), and their ability to do so
has been reported for several forms of cancers. Human pancre-
atic CSCs expressing the putative stem cell marker CD133 and
the chemokine receptor CXCR4 lost their metastatic activity
when the CXCR4+ population was depleted, suggesting that
CSCs may hijack cytokine-regulated migration-signaling path-
ways to initiate metastasis (Hermann et al., 2007). In breast
cancer, ectopic expression of Twist and Snail, two transcription
factors directly involved in epithelial mesenchymal transition
(EMT) and metastasis development, lead to increased expres-
sion of stem cells markers and enhanced tumorigenesis,
indicating that a tight connection between EMT activation and
CSC phenotype drives the metastatic process (Mani et al.,
2008). More recently, a CD26+ CSC population present in
both primary colorectal tumors and liver metastasis was demon-
strated to give rise to metastatic lesions in the liver when ortho-
topically injected in immunocompromised mice (Pang et al.,
2010). These studies provide a few examples of cancers where
CSCs isolated from both primary and metastatic tumors were
demonstrated to have the capacity to initiate metastasis. How-
ever, whether the cell-surface markers that identify CSCs play
a functional role in themolecular events within the tumor environ-
ment that drive tumorigenesis and result in the cancer spreading
to other organs has been difficult to pinpoint for most CSC pop-
ulations identified to date. This is an important goal for the field,
because understanding whether the cell-surface phenotype of
CSC is mechanistically linked with the metastatic process may
help develop effective therapeutic agents targeting CSCs.
CD44 is a widely expressed polymorphic integral membrane
adhesion molecule that binds hyaluronic acid and contributes
to cell-cell and cell-matrix adhesion, cell growth and trafficking,
EMT, and tumor progression (Orian-Rousseau, 2010). The vast
majority of tumors express CD44, whose detection in combina-
tion with other antigens is able to enrich for CSCs in several
different tumor types (Al-Hajj et al., 2003; Dalerba et al., 2007;
Lee et al., 2008; Patrawala et al., 2006; Pries et al., 2008; Zhang
Figure 1. Metastatic CRC Cells Express CD44v6
(A) Percentage of CD44v6 and CD133 on gated EpCAM+ cells assessed by flow cytometry on freshly purified CRC cells from parental tumor and corresponding
liver metastasis. Data are mean ± SD from independent experiments performed with cells from ten different patients.
(B) Flow cytometry profiles of EpCAM, CD44v6, and MET on primary, spheres, and SDAC.
(C) Immunofluorescence analysis of CD133, MET, and CD44v6 on paraffin-embedded sections of parental CRC and its liver metastasis tissue at the front of
invasion. Red arrowheads indicate tumor buds expressing CD133/MET/CD44v6. One representative experiment of 12, performed with tissues derived from
different patients, is shown. The scale bars represent 20 mm.
(D) Kinetics of in vivo whole-body imaging analysis of orthotopic tumor growth andmetastasis formation following injection of 53 103 CD44v6+ or CD44v6 cells.
Data aremean ± SD of four independent sets fromdifferent donors of six tumors per group. Right, hematoxylin and eosin (H&E) staining ofmouse caecum bearing
primary tumors generated by injection of CD44v6+ and CD44v6 cells. The scale bars represent 150 mm.
(legend continued on next page)
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CD44v6 in Metastatic Colon Cancer Stem Cellset al., 2008). CD44 transcripts undergo complex alternative
splicing, resulting in functionally different isoforms expressed
primarily on epithelial cells (To¨lg et al., 1993). Although the
expression of standard isoform (CD44s) has been more exten-
sively studied, the variant isoforms (CD44v) seem restricted to
subpopulations endowed with stem cell potential and cancer
development. This seems to be particularly true in the gut.
Although intestinal stem cells express both standard and variant
CD44 isoforms, CD44v, but not CD44s, isoforms promote the
generation of gut adenoma in mouse models of familial adeno-
matous polyposis (Zeilstra et al., 2014). Among CD44v isoforms,
CD44v6 seems to play a major role in cancer progression for
its ability to bind hepatocyte growth factor (HGF), osteopontin
(OPN), and other major cytokines produced by tumor micro-
environment (Orian-Rousseau, 2010). The major role of
CD44v6 involves cell migration and invasion. CD44v6 interacts
with hepatocyte growth factor receptor (MET) in the presence
of HGF and potentiates its signaling (Orian-Rousseau et al.,
2002). CD44v expression is downstream of the Wnt signaling
and induced by the b-catenin/Tcf-4 signaling pathway (Wielenga
et al., 2000). Nuclear b-catenin accumulates in the undifferenti-
ated CRC cells at the invasive front, whereas a gradual loss is de-
tected in the well-differentiated tumor areas, suggesting its role
as marker predictor for cancer metastasis (Brabletz et al., 2005).
The interaction between tumor and its microenvironment is
critical for cancer progression, which is promoted by different
cytokines produced by stroma or accessory cells present in
proximity to the tumor lesion (Whiteside, 2008). OPN is a cyto-
kine produced by fibroblasts and immune and endothelial cells
that is involved in several biological processes during bone turn-
over, tumorigenesis (Rangaswami et al., 2006), inflammation,
and immune response (Cantor and Shinohara, 2009). In CRC,
elevated CXCR4 expression correlated with advanced tumor
stages III/IV andmay help identify patients with higher probability
to metastasize to the liver (Schimanski et al., 2005). Likewise, the
functional expression of MET and HGF has been shown to pro-
vide a selective growth advantage to neoplastic cells at different
stages of tumor progression (Di Renzo et al., 1995).
Here, we investigated whether mechanisms regulating CD44
isoforms during developmental process would be mirrored by
colorectal (CR)-CSCs during tumorigenesis and metastatic
spread. We show that CR-CSCs are included in the CD44v6+
population and that such CD44v6 expression confers metastatic(E) Macroscopic analysis (left) and H&E staining (central panels) with correspo
orthotopic injection of CD44v6+ cells. Stomach (S), gut (G), liver (Li), lung (Lu
dissemination along the gut. Dotted circles emphasize metastatic foci. The scale
(F) Percentage of colon tumor and liver metastasis growth after 12 weeks in mice o
Data are mean ± SD of results obtained from 18 independent experiments perfo
(G) Tumor size measured on sections stained for H&E of orthotopic growth follow
CD44v6 populations. Samples were analyzed 16 weeks after cell injection. Data
seven different CRC patients.
(H) Size of subcutaneous tumors following injection of 1,000, 2,500, and 5,000 C
representative gross morphology of tumor xenografts grown for 12 weeks and ge
tumors per group derived from three separate patients.
(I) Percentage of CD44v6+ and CD44v6 sphere cells collected from the upper (up
medium from NIH 3T3 cells (NIH 3T3-CM), detected by flow cytometry.
(J) Clonogenic assay of spheres, CD44v6+- andCD44v6-enriched sphere cells, a
experiments, performed with cells from different patients. (Inset) Representa
(green color) and MET (red color) on spheres grown in the lower part of transwel
344 Cell Stem Cell 14, 342–356, March 6, 2014 ª2014 Elsevier Inc.potential to all CR-CSCs. Engagement ofMET and its coreceptor
CD44v6 in CR-CSCs activates an EMT program that promotes
cell motility, invasiveness, and metastasis. Furthermore, we
demonstrated that HGF, OPN, and stromal-derived factor 1a
(SDF-1) induce CD44v6 expression in CRC progenitor cells,
which increase the tumorigenic activity while acquiring the ability
to produce metastasis. Our data indicate CD44v6 as a molecule
that could be clinically exploited both as a biomarker and thera-
peutic target in CRC.
RESULTS
CD44v6 Expression Demarcates a Highly Tumorigenic
CR-CSC Population with Metastatic Potential
We and others previously demonstrated that CR-CSCs are en-
riched in tumor spheres or freshly isolated CD133+ cells (O’Brien
et al., 2007; Ricci-Vitiani et al., 2007; Todaro et al., 2007). Given
that CD44 has been reported as a CR-CSC marker (Dalerba
et al., 2007), we set out to investigate whether expression of
CD44 variants might stratify CR-CSCs into subpopulations
with distinct functional properties. Although several of the vari-
able CD44 exons were uniformly translated across patient-
derived CRC subsets, mRNA levels of CD44v5 and CD44v6
appeared considerably higher in sphere-propagated CSCs and
in freshly purified CD133+cells relative to sphere-derived differ-
entiated progeny and bulk primary cells (Figure S1A available
online). Analysis of CD44v5 mRNA in CD44v6+ cells purified
from patient tumors or spheres further suggested that CD44v5
and CD44v6 are translated in the same subset of CRC cells (Fig-
ure S1B). Interestingly, CD44v6 is significantly higher expressed
in metastatic lesions than in their corresponding primary tumors
(Figure 1A). In contrast, we found that CD44+-expressing cells
were equally present across CRC sphere cells and differentiated
progeny and in primary and metastatic tumors (Figure S1C).
Although MET, which is known to interact with CD44v6,
was prominently expressed in both primary and metastatic
CRCs (Figure S1D), subsets of CRC cells enriched in stem-like
cells, such as CD133+, CD166+, Lgr5+, EphB2bright, and tumor
spheres, all contain a small but consistently present CD44v6+
population (Figures 1B, S1E, and S1F). Intriguingly, immunofluo-
rescence analysis of tumor sections indicated that CD44v6+
cells were mainly located as tumor buds at the invasion front
of aggressive tumors and largely express CD133 (Figure 1C).nding magnifications (right) of tumors grown in the gut, liver, and lung after
), and tumors (T) are indicated. Red arrowheads highlight tumor multifocal
bars represent 200 mm.
rthotopically injected with freshly purified CD44v6+ and CD44v6 populations.
rmed with cells of six different patients.
ing injection of freshly purified parental cancer cells enriched in CD44v6+ and
are mean ± SD of the analysis of 21 tumor xenografts using cells purified from
D44v6+ and CD44v6 cells magnetically sorted from CRC spheres. Right, one
nerated by the injection of 5,000 cells. Data are mean tumor size ± SD of four
per) and lower (lower) layers of transwell chamber, in presence of conditioned
nd cells harvested as in (I). Data are expressed asmean ±SDof six independent
tive phase contrast image and immunofluorescence analysis for CD44v6
l. The scale bars represent 20 mm.
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Figure 2. HGF, OPN, and SDF-1 Increase the Number of CD44v6 Cells Sustaining the Metastatic Activity of CR-CSCs
(A) Percentage of CD44v6+ cells by flow cytometry in untreated and treated sphere cells with HGF, OPN, and SDF at the indicated time. Data are expressed as
mean ± SD of six independent experiments.
(B) Invasion assay of sphere cells using stem cell medium (SCM; medium) in presence of HGF, OPN, SDF alone, or in combination. Data are mean ± SD of five
independent experiments performed using cells from different patients.
(C) In vivo imaging analysis of tumor and metastasis outgrowth at the indicated time points. Xenografts were generated by using CRC sphere cells implanted
orthotopically and pretreated for 24 hr as in (A). Data are mean ± SD of four independent experiments using cells from different patients.
(D) Induction of CD44v6 expression in CD44v6 sphere cells untreated and stimulated with HGF, OPN, and SDF, alone or in combination for 24 hr by flow
cytometry.
(legend continued on next page)
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CD44v6 in Metastatic Colon Cancer Stem CellsBoth CD44v6+ and CD44v6 CRC sphere cells displayed
tumorigenic potential in vivo. However, CD44v6 cells generated
only small orthotopic tumors, whereas the CD44v6+ cell fraction
robustly generated metastatic lesions in the gut, liver, and lung
(Figures 1D, 1E, S2A, and S2B). Likewise, whereas freshly iso-
lated CD44v6+ cells were able to generate both orthotopic
tumors and metastasis, their negative counterparts grew locally
as small tumors, without forming distant lesions (Figures 1F–1H,
and S2C). The tumorigenic capacity of the CD44v6 popula-
tion was entirely lost in secondary recipients, suggesting
that CD44v6 cells include transient amplifying progenitors
and more differentiated nontumorigenic cells whereas meta-
static CR-CSCs are confined to the small CD44v6+ population
(Figure S2D).
CD26 has been reported as a marker of invasive and meta-
static CR-CSCs (Pang et al., 2010). Although more than 50%
of the CD44v6+/MET+/CD133+ cells express CD26 (Figure S2E),
CD44v6+/CD26 CR-CSCs showed considerable metastatic
potential in the orthotopic model (Figure S2F), indicating that
CD26 expression is not informative for metastatic activity of
the CD44v6 population.
To analyze the CD44v6+ and CD44v6 cells in more detail,
we investigated their invasive and clonogenic potential. In vitro
migration analysis confirmed that the invasion capability resided
entirely in the CD44v6+subset (Figure 1I), in which Twist andSnail
are translated (Figure S2G). Invading CRC cells also showed
MET phosphorylation, nuclear accumulation of b-catenin, com-
plete loss of E-cadherin, and acquisition of vimentin expression
(Figures S2H–S2J). Moreover, limiting dilution analysis showed
that the clonogenic activity of CD44v6+ and migrating cells
was significantly increased relative to bulk sphere cells,
whereas CD44v6 and nonmigrating cells were poorly clono-
genic (Figure 1J).
HGF, OPN, and SDF-1 Regulate CD44v6 Expression and
Drive the Metastatic Process
We next evaluated whether cytokines known to promote cancer
cell migration would affect tumorigenic properties and levels
of CD44v6 expression in CD44v6 CRC populations. In CRC
sphere cells, exposure to HGF, OPN, and SDF-1 promoted the
expression of CD44v6 with a minimal induction of CD44v5, while
concomitantly enhancing cell migration and metastatic activity
without altering MET expression (Figures 2A–2C and S3A–
S3C). Likewise, in the presence of these cytokines, CD44v6
progenitor cells acquired CD44v6 expression and gained in vivo
metastatic potential together with a more aggressive phenotype
(Figures 2D–2F and S3D). Consequently, freshly isolated primary
CRC samples formed distant lesions, which appeared as micro-(E) In vivo imaging analysis of tumor and metastasis growth at the indicated time
24 hr as in (D).
(F) Immunofluorescence analysis of GFP and CD44v6 on paraffin-embedded sec
derived by the orthotopic injection of CD44v6 cells transduced with LUC-GFP a
(G) Frequency of primary tumor andmetastasis formation after 12 weeks in immun
pretreated for 24 hr with HGF, OPN, and SDF.
(H) Tumor size evaluated on paraffin-embedded sections of CRC xenografts gener
(G). Data are mean ± SD of 21 tumor xenografts generated by freshly purified ca
(I) Invasion assay performed with NIH 3T3-CM (CM) up to 72 hr of sphere cells untr
independent experiments performed using cells from different patients.
346 Cell Stem Cell 14, 342–356, March 6, 2014 ª2014 Elsevier Inc.metastasis 3 months after injection only from cells that had been
exposed to HGF, OPN, or SDF-1 (Figures 2G, 2H, and S3E).
However, when primary CRC cells from CD44v6 samples
were exposed to HGF, OPN, or SDF-1 (Figure S3F), CD44v6
expression remained low in the vast majority of cells, suggesting
that only transiently amplified CD44v6 progenitors can be con-
verted to CD44v6+ cells. Whereas HGF binds to CD44v6 and
MET, SDF-1 binds to CXCR4, which is expressed by both
CD44v6 and CD44v6+ in parental and CRC sphere cells (Fig-
ure S3G). We found that blocking SDF-1 activity with the
CXCR4 antagonist AMD3100 in sphere cells reduced their
invasive capability (Figure 2I). Interestingly, SDF-1 blockage
also abrogated the upregulation of CD44v6 induced by HGF
and OPN (Figure S3H). Because both HGF and OPN are known
to upregulate CXCR4 and SDF-1, it is likely that both HGF and
OPN act via the CXCR4/SDF-1 axis in CD44v6 cells.
Cancer-Associated Fibroblasts Promote the
Tumorigenic and Metastatic Activity of CRC Stem and
Progenitor Cells
Cancer-associated fibroblasts (CAFs) are key players in the
tumor microenvironment known to secrete compounds that
potentiate tumor malignancy (Hanahan and Coussens, 2012).
Conditioned medium from CAFs (CAF-CM) increased the clono-
genic activity of sphere-cultured CRC cells, enhanced themigra-
tion of CD44v6+ cells, and turned nonmigrating CD44v6 cells
into migrating CD44v6+ cells, demonstrating that CAFs secrete
compounds that increase self-renewal and invasion potential
of CRC cells (Figures 3A and 3B). Both constitutive and cyto-
kine-induced CD44v6 expression was significantly reduced in
CRC spheres treated with fetal bovine serum (FBS) (Figures 3C
and S4A), suggesting that the absence of serum allows CAF-
CM to promote the expression of CD44v6 in undifferentiated
CRC cells. Whereas short-term exposure to CAF-CM or cyto-
kines resulted in a transient induction of CD44v6 in CD44v6
sphere cells, a prolonged stimulation maintained CD44v6
expression for several weeks, so that cells became functionally
similar to CD44v6+ cells (Figures S4B and S4C).
We found that both CD44v6+ and CD44v6 CRC sphere cells,
when treated with CAF-CM or cotransplanted subcutaneously
with CAFs, gave rise to larger primary and secondary tumors
(Figures 3D, 3E, and S4D). Immunohistochemical analysis
revealed that HGF, OPN, and SDF-1 could only be detected in
xenografts formed by CD44v6 cells coinjected with CAFs (Fig-
ure S4E), suggesting that these compounds are secreted by
CAFs during CRC tumorigenesis. Accordingly, primary cultured
CAFs and freshly isolated CD90+ cells from tumor specimens
produced significantly higher levels of HGF, OPN, SDF-1, andpoints. Xenografts were generated using CD44v6 sphere cells pretreated for
tions of primary tumor xenograft (primary) and its lung metastasis (metastasis)
nd treated with HGF. The scale bars represent 20 mm.
odeficient mice injected with freshly purified parental CRC cells, untreated and
ated by orthotopic injection of freshly purified parental cancer cells treated as in
ncer cells from seven different patients.
eated and treated with a-HGF, a-OPN, or AMD3100. Data aremean ± SD of five
Figure 3. CAFs Improve the Metastatic Potential of CRC Cells
(A) Clonogenic assay of spheres and CD44v6+- and CD44v6-enriched cells cultured in presence of SCM (medium) or conditioned medium from cancer-
associated fibroblasts (CAF-CM).
(B) Invasion assay of sphere cells (spheres) and CD44v6+- and CD44v6-enriched sphere cell populations cultured as in (A). Data are mean ± SD of five
independent experiments using cells from different patients.
(C) Flow cytometry analysis of CD44v6 in CD44v6+ and CD44v6 sphere cells untreated and treated with 10% FBS or CAF-CM at the indicated time points. Data
are expressed as mean ± SD of four independent experiments.
(legend continued on next page)
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subsets (Figures 3F and 3G).
CD44v6 and MET Are Required for CRC Metastasis
To confirm that CD44v6 is required for migration of tumorigenic
cells, we compared the inhibitory effect of CD44v6, HGF, or MET
targeting on CR-CSCs. Transduction of spheres with lentiviral
vectors encoding for specific CD44v6 and MET small hairpin
RNA (shRNA) sequences significantly reduced their mRNA
and protein levels, respectively (Figures S5A, S5B, and S5C),
while abolishing cell migration (Figure 4A). A similar inhibitory
effect was obtained using a blocking CD44v6 antibody or
shCD44v6, whereas HGF neutralization was slightly less effec-
tive (Figure 4A).
We next investigatedwhetherMET silencing in CD44v6+ CSCs
could have in vivo therapeutic benefits. Purified and depleted
CD44v6 cells from CRC spheres transduced with shCD44v6 or
inducible shMET were allowed to orthotopically grow into the
mouse caecum. MET and CD44v6 knockdown abrogated tumor
metastasis outgrowth, indicating that CSCs need both mole-
cules for tumor spreading (Figures 4B, 4C, and S5D), whereas
exogenous expression of CD44v6 restored the migration of
CD44v6 cells (Figures 4D, S5E, and S5F). To determinewhether
CD44v6 is required for the metastatic activity of CRC cells in
a syngeneic model, enriched and depleted CD44v6 cells
from the mouse colon-26 line were implanted into BALB/c
mice spleens and analyzed for their migration ability. Again,
CD44v6 cells were unable to colonize the liver, whereas
CD44v6+ cells were readily detected into the liver 30 min after
spleen injection (Figures 4E and S5G). Of note, exposure to
neutralizing antibody against CD44v6 was able to prevent tumor
spreading sustained by freshly isolated cells without affecting
the orthotopic engraftment (Figure 4F), indicating that CD44v6
may act as a functional marker of cells with metastatic potential
in CRC. Because CD44v6 and CD44v5 are coexpressed (Figures
4G, S1A, and S1B), we evaluate the involvement of CD44v5 in
the metastatic activity of CR-CSCs. Exogenous expression of
CD44v5 in CD44v5/CD44v6 CRC sphere cells promoted the
expression of CD44v6 (Figures S5H and S5I), allowing the cells
to become metastatic in the spleen-liver assay (Figure 4H). Alto-
gether, these results suggest that CD44v6 could be a promising
therapeutic target to prevent metastasis formation in CRC.
Wnt and BMP Pathways Control CD44v6 Expression and
CSC Activity
The activation of the Wnt/b-catenin pathway is the hallmark of
CR-CSCs. CD133+ CRC cells expanded in culture as tumor
spheres contain a subset of tumorigenic cells with constitutively(D) Kinetics of in vivo whole-body imaging analysis of metastasis formation at th
cells, untreated and treated with CAF-CM for 24 hr.
(E) Size of primary (8 weeks) and secondary (6 weeks) subcutaneous tumors g
cells, alone and together with CAF. Data are expressed as mean ± SD of four
representative Azan-Mallory analysis in CD44v6+ and CD44v6 tumor xenograft
(F) HGF, OPN, SDF, and TGF-b production in CAFs, spheres, and CD44v6+ and C
from different patients. Whiskers: Vmin, Vmax (log10).
(G) mRNA expression levels of HGF,OPN, TGF-b, and SDF on freshly sorted CD4
CD90/CD44v6 cells from colon cancer specimens. GAPDH was used as hous
experiments performed with cells from different patients.
348 Cell Stem Cell 14, 342–356, March 6, 2014 ª2014 Elsevier Inc.high Wnt signaling, which can be detected by a b-catenin/GFP
reporter (Vermeulen et al., 2010). By flow cytometry analysis,
we also found that the vast majority of CD44v6+ cells in CRC
spheres display high b-catenin activity (Figure 5A), in line
with the high tumorigenic activity of these cells. Interestingly,
immunofluorescence analysis of tumor sections indicated that
CD44v6+ cells at the invasion front of aggressive tumors largely
express nuclear b-catenin (Figure 5B). Of note, Wnt3a was able
to increase expression levels of CD44v6 and clonogenic and
migration activity of CRC stem and progenitor cells (Figures
5C–5E). Moreover, the analysis of CD44v6 transduced with
CD44v5 showed that the acquisition of CD44v6 paralleled the
activation of b-catenin (Figure 5F), confirming the prominent
role of the Wnt signaling pathway in this system. In accordance
with the functional differences observed in CD44v6+ and
CD44v6 cells, cytokines able to upregulate CD44v6 promoted
the expression of Wnt-, EMT-, and metastasis-related genes
(Figure 5G). Each of these cytokines was able to activate the
b-catenin pathway in CRC spheres (Figure 5H), in line with their
ability to promote a prometastatic phenotype in CD44v6 CRC
sphere cells.
Bone morphogenetic protein 4 (BMP4) and BMP2 are pro-
duced by differentiated CRC cells and are absent in cancer
stem and progenitor cells (Hardwick et al., 2004; Lombardo
et al., 2011). Because BMP4 promotes the differentiation of
CR-CSCs and antagonizes the Wnt pathway, we hypothesized
that BMPs could repress the expression of CD44v6. CD44v6+
cells gradually decreased their b-catenin activity in presence
of BMP4 (Figure 5I). Cytokine- and CAF-CM-induced CD44v6
expression was significantly reduced in CRC spheres treated
with BMP2 or BMP4 (Figure 5J), suggesting that the absence
of differentiating agents allows HGF, OPN, and SDF-1 to pro-
mote the expression of CD44v6 in undifferentiated CRC cells.
Thus, the ability of BMPs to promote the differentiation and
loss of tumorigenic activity of CR-CSCs is paralleled by the
repression of CD44v6 expression promoted by Wnt pathway.
PI3K Inhibition Reduces CD44v6 Expression and
Metastasis Formation in CRC
To investigate the signaling pathways involved in the metastatic
behavior of CR-CSCs, we analyzed the posttranslational modifi-
cations of the proteins commonly related to the metastatic
signaling pathways. Immunoblot analysis revealed a significant
downregulation of PTEN and a considerable upregulation of
phosphatidylinositol 3-kinase (PI3K) and activation of AKT in
CRC sphere cells treated with HGF, OPN, and SDF-1, whereas
a constitutive activation of the PI3K/AKT pathway was
observed in CD44v6+ cells (Figures 6A, 6B, and S6A). Inhibitione indicated time following spleen injection of CD44v6+ and CD44v6 sphere
enerated by injection of magnetically sorted CD44v6+ and CD44v6 sphere
independent experiments, performed with cells from different patients. Inset,
s. The scale bars represent 100 mm.
D44v6 cells. Data are mean ± SD of four independent experiments using cells
5/EpCAM/CD90+, CD45/EpCAM+/CD90/CD44v6+, and CD45/EpCAM+/
ekeeping control gene. Data are expressed as mean ± SD of five independent
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CD44v6 in Metastatic Colon Cancer Stem Cellsof PI3K/AKT pathway in CRC spheres caused a significant
reduction of cell viability, particularly in samples bearing PI3K
mutation (Figure S6B), and hampered the expression of
CD44v6 induced by HGF, OPN, and SDF-1 on CD44v6 cells
(Figures 6C and S6C). Of note, CD44v6+ cells were the major
subset dying in vitro after PI3K inhibition (Figure 6D). Moreover,
the analysis of early signaling showed that BMP4 upregulated
the expression of PTEN and impaired the activation of the
PI3K/AKT pathway promoted by HGF, OPN, and SDF-1 (Figures
6E and S6D). To investigate whether the dependence of
CD44v6+ cells to the PI3K/AKT pathwaymay be exploited to pre-
vent or reduce metastasis formation in CRC, we determined the
effect of treatment with the PI3K inhibitor BKM120 on the ortho-
topic preclinical model. Such treatment considerably reduced
the metastatic spreading of CRC cells, regardless of the
presence of PI3K-activating mutations (Figures 6F and S6E).
Accordingly, exogenous expression of PI3K re-established the
expression of CD44v6 and the in vivo migration of CD44v6 cells
(Figures S6F–S6H), confirming that the PI3K pathway plays a
major role in promoting the metastatic activity of CRC cells.
CD44v6 Expression Is a Biomarker for the Clinical
Outcome of CRC Patients
We next explored the clinical relevance of CD44v6 as a prog-
nostic biomarker. In linewith ameta-analysis of 511 patients pro-
posing a correlation between detection of CD44v6 and worse
overall survival (Fan et al., 2012; Saito et al., 2013), the analysis
of a large cohort of primary and metastatic CRCs showed a sig-
nificant negative correlation between CD44v6 expression and
survival probability of CRC patients (Figures 7A–7D). This corre-
lation was not detectable in patients with stage I and II, most
likely because a higher number of patients and a longer followup
would be required to detect differences in low-stage tumors (Fig-
ure S7A). Of note, multivariate analysis indicated that CD44v6
is an independent negative prognostic factor in both cohorts of
patients (Figure S7B).
Given that HGF, OPN, and SDF-1 induce the expression
of CD44v6 in immature CRC cells, we investigated the possible
correlation of these cytokines with the presence of CD44v6 in tu-
mor specimens from CRC patients. The analysis of ten patientsFigure 4. Inhibition of CD44v6 and MET Hampers the Metastatic Poten
(A) Invasion assay of sphere cells untreated (medium) and treated with a-CD44
shRNA (shCD44v6). a-HGFwas added to the lower part of transwell containing NIH
from different patients.
(B) In vivowhole-body imaging analysis of orthotopic xenografts andmetastasis gr
scramble CD44v6+ (Scr CD44v6+), scramble CD44v6 (Scr CD44v6), shCD44
CD44v6+, or shMET CD44v6. Data are expressed as mean ± SD of five indepe
(C) Kinetics of in vivo whole-body imaging analysis of orthotopic xenografts and
transduced with Scr CD44v6, shCD44v6, Scr MET, or doxycycline-inducible sh
experiments.
(D) Kinetics of in vivo imaging analysis of metastatic formation induced by injection
synthetic gene, at the indicated time points after splenectomy.
(E) In vivo imaging analysis of syngeneic BALB/c mice obtained by spleen injectio
(F) Growth percentage of primary tumors and corresponding liver metastasis sust
neutralizing antibody against CD44v6 (a-CD44v6). Data are mean ± SD of results o
patients.
(G) Flow cytometry profiles of CD44v5/CD44v6 in CD44v6+CRC cells. Data are rep
(H) Kinetics of in vivo imaging analysis of metastatic colony formation induced b
CD44v5 synthetic gene, at the indicated time points after splenectomy (left pa
LUC-GFP EV and CD44v5 synthetic gene generated 30 min after splenectomy (r
350 Cell Stem Cell 14, 342–356, March 6, 2014 ª2014 Elsevier Inc.showed that HGF,OPN, and SDF-1 are present at higher levels in
tumors with increased number of CD44v6+ cells as compared
with tumors with fewer or no CD44v6+ cells (Figure S7C), sug-
gesting that the three cytokines contribute to increase the num-
ber of CD44v6+ cells in tumors of CRC patients.
DISCUSSION
Here, we demonstrated that CR-CSCs express CD44v6, which
is a functional marker able to confer the ability to migrate at
distant sites and develop CRC metastasis, as confirmed by the
significant inverse correlation between patient survival and
CD44v6 expression. Several groups have identified tumorigenic
populations with stem-like features in CRC (Barker et al., 2007;
Dalerba et al., 2007; Huang et al., 2009; O’Brien et al., 2007;
Ricci-Vitiani et al., 2007; Todaro et al., 2007; Vermeulen et al.,
2008, 2010). These cells are able to promote tumor growth and
are regarded as an ideal cell target to obtain effective therapies.
However, the growth of primary tumors is usually not life-threat-
ening, unlike the occurrence of metastatic lesions (Valastyan and
Weinberg, 2011). Because MET is widely expressed in CRC
(Takeuchi et al., 2003), the concomitant expression of CD44v6
and MET in all CR-CSCs empowers these cells to form metas-
tasis and severely affect patient prognosis (Minoo et al., 2010;
Peng et al., 2008).
EMT is exploited by cancer cells to increase self-renewal and
migration through a process that favors the emergence of CSCs
(Mani et al., 2008). We show that CD44v6+ CRC cells display
b-catenin activation and EMT traits coupled with a considerable
migratory activity, which explains the metastatic features of
immunocompromised mice treated with these cells. Our data
reveal that the EMT and metastatic potential of CR-CSCs is
increased by microenvironmental signals promoting the expres-
sion of CD44v6. HGF, SDF-1, and OPN are potent inducers of
CD44v6 and providemetastatic activity to tumorigenic cells. Tar-
geting MET or CD44v6 completely prevented the invasive capa-
bility of the tumorigenic CRC cells, indicating that the metastatic
potential depends on signaling generated by HGF via CD44v6
and MET. These receptors cooperate to activate the PI3K/AKT
pathway, which promotes migration and survival signaling intial of CR-CSCs
v6 or transduced with control shRNA (Scr), MET shRNA (shMET), or CD44v6
3T3-CM (CM). Data aremean ± SD of six independent experiments using cells
owth at the indicated weeks generated by 53 103 sphere cells transducedwith
v6 CD44v6+ (shv6 CD44v6+), shCD44v6 CD44v6 (shv6 CD44v6), shMET
ndent experiments.
metastasis growth at the indicated weeks generated by 5 3 103 sphere cells
MET (shMET TetR). Data are expressed as mean ± SD of three independent
of CD44v6CRC sphere cells transduced with empty vector (EV) andCD44v6
n of enriched CD44v6+ and CD44v6 colon-26 cells, 30 min after splenectomy.
ained by parental cancer cells treated with isotype-matched control (IMC) and
btained from 12 independent experiments performed with cells of four different
resentative of four independent experiments using cells fromdifferent patients.
y injection of CD44v6 CRC sphere cells transduced with LUC-GFP EV and
nel). In vivo whole-body imaging analysis of migrating cells transduced with
ight panels).
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Figure 5. CD44v6 Expression Is Critically Regulated by the Wnt Pathway
(A) Flow cytometry analysis of IMC and CD44v6 on colon cancer sphere cells transduced with TOP-destabilized GFP (dGFP).
(B) Expression of CD44v6 (red color) and b-catenin (green color) on paraffin-embedded sections of parental CRC and its liver metastasis tissue at the front of
invasion. Nuclei were counterstained with Toto-3 (blue color). The scale bars represent 20 mm.
(C) Clonogenic assay of spheres and CD44v6+ and CD44v6 enriched cells cultured in presence of CAF-CM or treated with Wnt3a.
(D) Migration assay of bulk (spheres) and CD44v6+ and CD44v6 sphere cells untreated (medium) and pretreated with Wnt3a for 6 hr.
(E) Flow cytometry analysis of CD44v6 on sphere cells untreated and treated with Wnt3a or TGF-b. Data are representative of three independent experiments.
(F) Immunofluorescence analysis of b-catenin (red color) and GFP on CD44v6 CRC sphere cells transduced with LUC-GFP EV and CD44v5 synthetic gene
(green color). Nuclei were stained with Toto-3 (blue color). The scale bars represent 10 mm.
(legend continued on next page)
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CD44v6 in Metastatic Colon Cancer Stem CellsCR-CSCs. Activation of Wnt signaling plays a key role in main-
taining the stem cell pool in the gut and promoting self-renewal
of CR-CSCs (de Lau et al., 2011; Leedham et al., 2013; Ootani
et al., 2009; van Es et al., 2012). Cytokines released in the micro-
environment contribute significantly to maintain the undifferenti-
ated status and clonogenic activity of the tumorigenic cells
(Bissell and Labarge, 2005; Medema and Vermeulen, 2011; Ver-
meulen et al., 2010). Our data indicate that this property is not
confined to HGF (Vermeulen et al., 2010), but it is shared by
OPN and SDF-1, which enhance b-catenin activation in CR-
CSCs. A similar effect may be mediated by TGF-b, which is pro-
duced by both CAFs and CD44v6+ cells. Whereas CAFs seem to
play a key role in the induction of CD44v6, it is likely that auto-
crine production of OPN and TGF-b may contribute to promote
the metastatic activity of CD44v6+ cells. The inability of all these
cytokines to induce the expression of CD44v6 on more-differen-
tiated CRC cells may be related to the low activation of b-catenin
observed in these cells, despite the presence of genomic alter-
ations that should provide a constitutive activation of the Wnt
pathway. Thus, CD44v6 expression appears as part of a more
complex system that confers self-renewal and metastatic prop-
erties to CR-CSCs. Targeting CD44v6 expression prevented
metastasis formation without affecting the growth of primary
tumors. Likewise, delivery of CD44v6 in negative cells restores
migration and in vivo colonization, without providing self-renewal
properties to target cells.
We recently demonstrated that BMP4 counteracts Wnt activ-
ity in CR-CSCs and promotes their differentiation via upregula-
tion of PTEN and inhibition of PI3K (Lombardo et al., 2011), which
maintain the undifferentiated status of the tumorigenic popu-
lation (Vermeulen et al., 2008). CD44v6+ cells show enhanced
activation of the PI3K/AKT pathway, which is triggered by ligand
binding and by the epigenetic silencing of PTEN that character-
ized CR-CSCs (Lombardo et al., 2011; Ricci-Vitiani et al., 2010).
PI3K promotes the expression of CD44v6 in CRC progeni-
tors, whereas its inhibition impairs migration and survival of
CD44v6+ CRC cells, which are significantly more sensitive to
PI3K inhibition than the CD44v6 counterpart. Because clinical
trials with available drugs targeting PI3K or HGF pathways
have not been designed in the adjuvant setting, these findings
may have considerable therapeutic implications (Ghiso and
Giordano, 2013; Rodon et al., 2013).
Although some CD44v6 cells could be tumorigenic and
develop small tumors, most tumorigenic activity seems to be
confined in the CD44v6+ population, which contains virtually all
the cells with high b-catenin activation. Because there is a signif-
icant overlap between tumorigenic and metastagenic cells, it is
likely that the relative density of CSCs in CRC directly correlates
with the metastatic propensity of tumor lesions. In this context,
CD44v6 appears as a key functional biomarker critically involved
in the main features of cancer progression.(G) Clustergrams of up- and downregulated Wnt targets and epithelial-mesenchy
CD44v6+ and CD44v6 cells, untreated and treated with HGF, OPN, SDF, and C
three different patients.
(H) Flow cytometry analysis of TOP-dGFP in CD44v6-depleted CRC sphere cells
(I) Flow cytometry analysis of CD44v6 in TOP-dGFP transduced CD44v6+ cells u
(J) Flow cytometry profiles of representative IMC andCD44v6 in CD44v6 sphere
48 hr (upper panels) and in CRC sphere cells untreated (medium) or treated with
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Five-week-old nonobese diabetic/severe combined immunodeficiency mice
from Charles River Laboratories were maintained in accordance to the institu-
tional guidelines of the University of Palermo Animal Care Committee.
Tissue Collection an Isolation and Culture of Cancer Cells
Colorectal cancer tissues were obtained at the time of resection from 36
patients (age range 52–78 years) and liver metastasis from 18 matched
patients, in accordance with the ethical standards of the Institutional Commit-
tee on Human Experimentation (see Table S1). Normal colon mucosa was
obtained from the histologically uninvolved resection.
Sphere purification and sphere-derived adherent cultures (SDACs) were
obtained as previously described (Lombardo et al., 2011; Todaro et al., 2007).
Primary fibroblasts were isolated from colorectal cancer tissues, cultured in
presence of 10% FBS Dulbecco’s modified Eagle’s medium in adherent con-
ditions, and indicated as CAFs. Murine colon carcinoma cells (colon-26) were
cultured in medium supplemented with 2 mM L-glutamine and 10% FBS in
adherent conditions (CLS Cell Lines Service).
Flow Cytometry and Magnetic Sorting
Cells, where indicated, were stained with primary conjugated EpCAM-
PerCP–Cy5.5 (EBA-1; mouse immunoglobulin G1 [IgG1]; BD Biosciences),
CD44v6-antigen-presenting cell (APC) (2F10; mouse IgG1; R&D Systems),
MET-fluorescein isothiocyanate (FITC) (95106; mouse IgG1; R&D Systems),
CD44v5 (3D2; mouse IgG1; R&D Systems) antibodies, or corresponding
isotype-matched controls. Magnetic cell separation was performed on cells
stained with CD44v6 (VFF-7; mouse IgG1; Abcam) rinsed and incubated
with microbeads (130-047 102 anti-mouse IgG1 microBeads; Miltenyi Biotec).
Quality of sorting was monitored by flow cytometry with specific antibody for
CD44v6-APC. Freshly purified CRC cells were stained for CD45-PerCP-Cy5.5
(TU116; mouse IgG1k; BD Biosciences), CD90-FITC (5E10; mouse IgG1k; BD
Biosciences), EpCAM-phycoerythrin (BD Biosciences), and CD44v6-APC;
sorted; and collected in TRIzol for reverse transcriptase analysis. In order
to analyze changes of CD44v6 expression, flow cytometry analyses
were assessed on cells treated with HGF (100 ng/ml), OPN (1 mg/ml), SDF
(100 ng/ml), 10% FBS, CAF-CM, transforming growth factor-beta1 (recombi-
nant human TGF-b1; 4 ng/ml; Peprotech), and BKM120. Cells were also pre-
or posttreated with BMP2 or BMP4 (100 ng/ml; R&D Systems) up to 6 days.
Immunofluorescence/Immunohistochemistry
Cells were fixed and permeabilized as previously reported (Todaro et al., 2007)
and exposed overnight at 4C to antibodies against CD133 (AC133; mouse
IgG1; Miltenyi Biotec), MET (c-28; rabbit IgG; Santa Cruz Biotechnology),
CD44v6 (2F10; mouse IgG1; R&DSystems), b-catenin (H102; rabbit IgG; Santa
Cruz Biotechnology), or isotype-matched controls. Then, cells were labeled
with secondary antibodies (Invitrogen). Nuclei counterstaining was performed
using Toto-3 iodide.
Tissue microarrays (TMAs) slides were exposed to specific antibodies
against CD44v6, examined microscopically by three independent observers
blinded to clinicopathological information, and stratified according to the
CD44v6 expression.
Invasion Assay
Cells (1.53 103), untreated and treated with hepatocyte growth factor (recom-
binant humanHGF; 100 ng/ml; Peprotech), osteopontin (OPN; 1 mg/ml; Sigma),
stromal-cell-derived factor-1a (recombinant human SDF-1a; 100 ng/ml;
Peprotech), CAF-CM, neutralizing antibody against CD44v6 (15 mg/ml; 2F10;
mouse IgG1; R&D Systems), isotype-matched control (15 mg/ml; humanmal transition (EMT)- and tumor metastasis (TM)-related genes in spheres and
AF-CM for 24 hr. Gene expression profiles are derived from cells purified from
untreated (medium) or treated with HGF, OPN, and SDF. SSC, side scatter.
ntreated (medium) or treated with BMP4 up to 6 days.
cells cultured with medium or CAF-CM and posttreated with BMP4 or BMP2 for
BMP4 with or without HGF, OPN, and SDF (lower panels).
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Figure 6. PI3K Inhibition Promotes Death of CD44v6 Cell Fraction
(A) Foldprotein level changesofPI3K,AKT, phosho-AKT (pAKT), andPTEN ineight different sphere cell linesuntreatedand treatedwithHGF,OPN, andSDF for 24hr.
(B) Relative protein expression levels of PI3K, AKT, pAKT, and PTEN onCD44v6+ andCD44v6 sphere cells. Data aremean ± SDof five independent experiments
performed using different cell lines. OD, optical density.
(C) CD44v6 expression in CD44v6 sphere cells untreated (medium) and treated with HGF, OPN, SDF, and CAF-CM, alone or in combination with BKM120 for
48 hr. Data are expressed as mean ± SD of six independent experiments.
(D) Confocal microscopy analysis of apoptotic events on cytospun disaggregated spheres and CD44v6+ and CD44v6 cells treated with DMSO or 1 mMBKM120
and stained for CD44v6 (red color) and TUNEL (green color, white arrows). Nuclei were counterstained by Toto-3 (blue color). Positive control was assessed with
DNase pretreated cells. The scale bars represent 20 mm.
(legend continued on next page)
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Figure 7. CD44v6 Expression Correlates
with Poorer Prognosis
(A) Representative immunohistochemical analysis
of CD44v6 on CRC cores in no detectable (0), up
to ten positive cells (1), 11–50 positive cells (2), and
over 50 positive cells (3). The scale bars represent
50 mm. n.d., no detectable.
(B) Association of CD44v6 expression with score
2/3 and the pathological staging in CRC patients
included in the TMAs provided by TRISTAR
technology group (Tri) and National Institutes of
Health (NIH).
(C) Kaplan-Meier survival curves basedonCD44v6
expression, according to (A), in all patients
analyzed in Tri and NIH TMAs.
(D) Kaplan-Meier survival curves according to
CD44v6 expression (0/1 and 2/3) as in (A)
analyzed in patients with stages III to IV.
Cell Stem Cell
CD44v6 in Metastatic Colon Cancer Stem CellsCD3ε; UCHT1; mouse IgG1; R&D Systems), Wnt3a (150 ng/ml; R&D Systems)
or transduced with control shRNA (Scr), MET shRNA (shMET), or CD44v6
shRNA (shv6), were plated into Matrigel-coated (BD Biosciences) transwell of
8 mm pore size (Corning Life Sciences). Supernatant of National Institutes of
Health (NIH) 3T3 cells cultured in stem cell medium (SCM) (CM) or SCM alone
(medium) or supplemented with cytokines were used as chemoattractant(E) Fold change of PI3K, AKT, pAKT, and PTEN in CD44v6 sphere cells untreated and treated with HGF, OP
BMP4 for additional 24 hr.
(F) In vivo imaging analysis of orthotopic tumor and liver metastasis growth at the indicated weeks generated
BKM120. Data are representative of four independent experiments.
354 Cell Stem Cell 14, 342–356, March 6, 2014 ª2014 Elsevier Inc.in the transwell lower part. Antibodies against
HGF (10 mg/ml; 24612; mouse IgG1; R&DSystems)
and OPN (5 mg/ml; AF1433; goat IgG; R&D Sys-
tems) were mixed with conditioned medium and
placed in the lower part of transwell. AMD3100
(50 mM; Sigma-Aldrich) was added to sphere
cells for 90 min and replaced every 6 hr up to
72 hr in the upper part of the transwell. Migration
was observed and counted microscopically up to
72 hr.
Clonogenic Assay
Cells were plated in presence of stem cell medium,
CAF-CM or Wnt3a, replaced every 5 days, on
ultra-low-adhesion 96-well plates at a concentra-
tion of a single cell per well. Wells containing either
none or more than one cell were excluded for the
analysis.
Animals and Orthotopic Tumor Model
Orthotopic xenografts were obtained using either
5 3 103 or 15 3 103 CRC sphere cells or freshly
purified parental cancer cells CD44v6+- and
CD44v6-enriched cells. Intrasplenic injection
of 3 3 105 luciferase (LUC)/GFP-transduced
CD44v6+ and CD44v6 cells, untreated and
treated with CAF-CM for 24 hr, or CD44v6 cells
overexpressing CD44v6 or CD44v5 was per-
formed to evaluate the metastatic potential.
Subcutaneous xenografts were obtained by the
injection of enriched CD44v6+ and CD44v6 cells,
alone or in combination with CAF (2.5 3 103 cells;
ratio 1:1). Secondary tumors were generated by
the inoculation of 5 3 103 primary bulk xenograftcells. In the syngeneic model, 3 3 105 CD44v6+ and CD44v6 colon-26 cells
transduced with LUC/GFP were injected into the spleen of BALB/c-mice.
Cytokines Quantification
Quantification for HGF, OPN, SDF-1, and TGFb production was assessed by
using multiplex Bio-Plex Pro Assays (Bio-Rad; Human Cancer BiomarkerN, and SDF for 24 hr, alone or in combination with
by CRC sphere cells treated with PBS (vehicle) and
Cell Stem Cell
CD44v6 in Metastatic Colon Cancer Stem CellsPanel 1-4 No. 171-AC500M; Human Cytokine SDF-1a Set No. 171-B6019M;
TGF-b 3-plex Assay No. 171-W4001M). Raw data (mean fluorescent intensity)
from all kits were analyzed by Bio-Plex Software (Bio-Rad).
Real-Time PCR
Quantitative real-time PCR analysis was performed in a master mix containing
the following primer sets: Hs00300159_m1 (HGF), Hs00959010_m1 (OPN),
Hs00998133_m1 (TGF-b1), Hs00171022_m1 (SDF-1), and Hu-GAPDH
(Applied Biosystems). Data processing and statistical analysis were performed
using the ABI PRISM SDS software v2.1 (Applied Biosystems).
The RT2 Profiler PCR array was assessed for genes related to Wnt targets,
EMT, and tumor metastasis (TM) (PAHS-243ZR-12, PAHS-090ZR, PAHS-
028ZR-12; SuperArray Bioscience). Cycle threshold values were calculated
for all the genes present on the array and normalized using the average of
five housekeeping genes (ACTB, B2M, HPRT1, RPLP0, and GAPDH). RT2
Profiler PCR array data analysis was represented by clustergrams based on
Pearson’s correlation of 2^ (DCt).
Statistical Analysis
Data were expressed as mean ± SD. Statistical significance was determined
by ANOVA (one-way or two-way) with Bonferroni posttest.
For TMA analysis, associations between categorical variables were tested
by the Pearson Chi-Square test, Fisher Exact tests, or Chi square for trend,
when appropriate. The receiver-operating characteristic curve analysis was
used in order to find possible optimal cutoffs of the CD44v6 capable of splitting
patients into groups with different outcomes probabilities. Kaplan-Meier
method was used to estimate survival curves, whereas differences between
subgroups were assessed by the log rank test. All significance was defined
at the p < 0.05 level.
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